STAAR Surgical Company
STAAHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeSTAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the. Valued at $1.13B, STAA is a small-cap name in its sector. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Market Cap
$1.13B
Beta
1.18
P/E (TTM)
282.63
P/E (Fwd)
20.34
EPS (TTM)
$0.08
EPS (Fwd)
$1.11
ROE
1.1%
ROA
5.7%
Cash
$181.5M
Total Debt
$35.9M
Free CF
$15.3M
52W Change
-13.9%
Annual Financials
Cash vs Debt
Where STAA stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, STAA finished 12.39% below its 150-day moving average ($24.93) and 7.38% below its 200-day moving average ($23.58). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is STAA overbought or oversold?
At the October 15, 2026 close, STAA's RSI(14) was 71.2, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
STAAR Surgical Company holds $181.5M in cash against $35.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $15.3M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 1.1% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has pulled back from $284.4M (2022) to $239.4M (2025), a 16% decline worth watching.
With cash comfortably exceeding debt, STAA has financial flexibility that may help navigate uncertain periods. At over 50x earnings, STAA carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing STAA.